



April 2020

Dear Optum360 2020 HCPCS Level II Expert Customer:

The Centers for Medicare and Medicaid Services (CMS) has issued the following updates.

Included below are the changes that can be marked in your book. Our customer service team is available should there be any questions, by calling 1.800.464.3649, option 1.

Thank you for your patience and support of our ongoing efforts to deliver quality products. We value you as an Optum360 customer.

Sincerely,

Optum360

www.optum360coding.com

The following are changes effective March 1, 2020:

New Codes

- G2023 Specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source
- G2024 Specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source

New Modifier

- CS Cost-sharing for specified COVID-19 testing-related services that result in an order for or administration of a COVID-19 test

The following are changes effective April 1, 2020:

New Codes

- C9053 Injection, crizanlizumab-tmca, 1 mg
- C9056 Injection, givosiran, 0.5 mg
- C9057 Injection, cetirizine HCl, 1 mg
- C9058 Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo) 0.5 mg
- G1012 Clinical Decision Support Mechanism AgileMD, as defined by the Medicare Appropriate Use Criteria Program
- G1013 Clinical Decision Support Mechanism EvidenceCare Imaging Advisor, as defined by the Medicare Appropriate Use Criteria Program
- G1014 Clinical Decision Support Mechanism InveniQA Semantic Answers in Medicine, as defined by the Medicare Appropriate Use Criteria Program
- G1015 Clinical Decision Support Mechanism Reliant Medical Group, as defined by the Medicare Appropriate Use Criteria Program
- G1016 Clinical Decision Support Mechanism Speed of Care, as defined by the Medicare Appropriate Use Criteria Program

- G1017 Clinical Decision Support Mechanism HealthHelp, as defined by the Medicare Appropriate Use Criteria Program
- G1018 Clinical Decision Support Mechanism INFINX, as defined by the Medicare Appropriate Use Criteria Program
- G1019 Clinical Decision Support Mechanism LogicNets, as defined by the Medicare Appropriate Use Criteria Program
- G2168 Services performed by a physical therapist assistant in the home health setting in the delivery of a safe and effective physical therapy maintenance program, each 15 minutes
- G2169 Services performed by an occupational therapist assistant in the home health setting in the delivery of a safe and effective occupational therapy maintenance program, each 15 minutes
- U0001 CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel
- U0002 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC

Revised Codes

- G2061 Qualified nonphysician health care professional online assessment and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes
- G2062 Qualified nonphysician health care professional online assessment and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes
- G2063 Qualified nonphysician qualified health care professional assessment and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes

Deleted Codes

G1000 Clinical Decision Support Mechanism Applied Pathways, as defined by the Medicare Appropriate Use Criteria Program

The following are changes effective April 14, 2020 (reportable for services provided on March 18, 2020 and forward):

New Codes

U0003 Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R

U0004 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R